Adenosine A(2A) receptors modify motor function in MPTP-treated common marmosets

NeuroReport

Volumn 9, Issue 12, 1998, Pages 2857-2860

  Kanda, Tomoyuki ^a,b   Tashiro, Tomomi ^a   Kuwana, Yoshihisa ^a,b   Jenner, Peter ^b  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Adenosine A(2A) receptors; APEC; Common marmosets; DPCPX; KW 6002; MPTP; Parkinson's disease

Indexed keywords

2 [4 [2 (2 AMINOETHYLAMINO)CARBONYLETHYL]PHENETHYLAMINO] 5' N ETHYLCARBOXAMIDOADENOSINE; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; ISTRADEFYLLINE; UNCLASSIFIED DRUG; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 ((2 AMINOETHYLAMINO)CARBONYLETHYLPHENYLETHYLAMINO) 5' N ETHYLCARBOXAMIDOADENOSINE; 2-((2-AMINOETHYLAMINO)CARBONYLETHYLPHENYLETHYLAMINO)-5'-N-ETHYLCARBOXAMIDOADENOSINE; ADENOSINE; ADENOSINE RECEPTOR; DOPAMINE; DRUG DERIVATIVE; PHENETHYLAMINE DERIVATIVE; PURINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; DRUG RECEPTOR BINDING; DRUG TARGETING; FEMALE; MALE; MARMOSET; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR DENSITY; SUBCUTANEOUS DRUG ADMINISTRATION; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG POTENTIATION; MOTOR ACTIVITY; MOVEMENT (PHYSIOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADENOSINE; ANIMALS; CALLITHRIX; DOPAMINE; FEMALE; MALE; MOTOR ACTIVITY; MOVEMENT; PARKINSON DISEASE, SECONDARY; PHENETHYLAMINES; PURINES; RECEPTOR, ADENOSINE A2A; RECEPTORS, PURINERGIC P1;

EID: 0032563388     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199808240-00032     Document Type: Article

References (18)

1. Daly JW, Butts Lamb P and Padgett W. Cell Mol Neurobiol 3, 69-74 (1983).
2. Brurns RF, Lu GE and Pugsley TA. Mol Pharmacol 29, 331-346 (1986).
3. Fredholm BB, Abbracchio MP, Bumstock G et al. Pharmacol Rev 46, 143-156 (1994).
4. Jalvis MF and Williams M. Eur J Pharmacol 168, 243-246 (1991).
5. Schiffmann SN, Libert F, Vassalt G and Vanderhaeghen J-J. Neurosci Lett 130, 177-181 (1989).
6. Schiffmann SN, Jacobs O and Vanderhaeghen J-J. J Neurochem 57, 1062-67 (1991).
7. Kurokawa M, Kirk IP, Kirkpatrik A et al. Br J Pharmacol 113, 43-48 (1994).
8. Kurokawa M, Koga K, Kase H et al. J Neurochem 66, 1882-1888 (1996).
9. Kanda T, Shiozaki S, Schimada J et al. Eur J Pharmacol 256, 263-268 (1994).
10. Kanda T, Jackson MJ, Smith LA et al. Ann Neurol 43, 507-513 (1998).
11. Dunwiddie TV. Int Rev Neurobiol 27, 63-139 (1986).
12. Shirnada J, Koike N, Nonaka H et al. Bioorg Med Chem Lett 7, 2349-2352 (1997).
13. Griebel G, Saffoy Spittler M, Misslin R et al. Psychopharmacology 103, 541-544 (1991).
14. Ji XD, Stiles GL van Galen PJ and Jacobson KA. J Receptor Res 12, 149-169 (1992).
15. Nikodijevic O, Sarges R, Daly JW and Jacobson KA. J Pharmacol Exp Ther 259, 286-294 (1991).
16. Monopoli A, Casati C, Lozza G et al. J Pharmacol Exp Thera 285, 9-15 (1998).
17. Mori A, Shindou T, Ichimura M et al. J Neurosci 16, 605-611 (1996).
18. Richardson PJ, Kase H and Jenner PG. Trends Pharmacol Sci 18, 338-344 (1997).